Dramatic response of vemurafenib-induced cutaneous lesions upon switch to Dual BRAF/MEK inhibition in a metastatic melanoma patient

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 496-500

  Peters, Solange ^a   Bouchaab, Hasna ^a   Zimmerman, Stefan ^b   Bucher, Maya ^a   Gaide, Olivier ^a   Letovanec, Igor ^a   Homicsko, Krisztian ^a   Michielin, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; SULFONAMIDE;

AGED; APOPTOSIS; ARTICLE; CANCER CONTROL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; GENE MUTATION; HUMAN; KERATOACANTHOMA; LIVER TOXICITY; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN TOXICITY; TREATMENT RESPONSE; BIOPSY; CELL PROLIFERATION; GENETICS; INCIDENCE; MELANOMA; METABOLISM; METASTASIS; MUTATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOPSY; CELL PROLIFERATION; DACARBAZINE; FEMALE; HUMANS; INCIDENCE; INDOLES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84925941557     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000055     Document Type: Article

References (12)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
2. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-215.
3. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387-390.
4. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-3096.
5. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-221.
6. Shi H, Moriceau G, Kong X, Lee M-K, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
7. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
8. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
9. Ascierto PA, Minor D, Ribas A, Lebbé C, O'Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-3211.
10. O'Bryan K, Sherman W, Niedt GW, Taback B, Manolidis S, Wang A, Ratner D. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2013;69:595-602.e1.
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
12. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-255.